Abbott Laboratories 2021 Q3 Form 10-Q Summary
Business context and reporting period
Abbott Laboratories reported results for the three and nine months ended September 30, 2021, compared with the corresponding 2020 periods. The company operates through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The filing was signed November 3, 2021.
Key financial metrics
| Metric | Q3 2021 | Q3 2020 | 9M 2021 | 9M 2020 |
|---|---|---|---|---|
| Net sales | $10.928 billion | $8.853 billion | $31.607 billion | $23.907 billion |
| Operating earnings | $2.546 billion | $1.495 billion | $6.047 billion | $2.925 billion |
| Net earnings | $2.100 billion | $1.232 billion | $5.082 billion | $2.333 billion |
| Diluted EPS | $1.17 | $0.69 | $2.83 | $1.30 |
| Gross margin | 54.8% | 49.4% | 51.6% | 49.2% |
| Operating margin | 23.3% | 16.9% | 19.1% | 12.2% |
| Net margin | 19.2% | 13.9% | 16.1% | 9.8% |
- Q3 sales increased 23.4% year over year, including a 1.0% favorable foreign-exchange effect. Excluding foreign exchange, sales increased 22.4%.
- Nine-month sales increased 32.2%, or 29.6% excluding foreign exchange.
- Nine-month net cash from operating activities was $7.466 billion versus $4.103 billion in 2020. Capital expenditures were $1.271 billion, dividends paid were $2.404 billion, and share purchases were $1.325 billion.
- Cash and cash equivalents were $9.302 billion at September 30, 2021, compared with $6.838 billion at December 31, 2020. Working capital increased to $10.6 billion from $8.5 billion.
- Total debt was approximately $18.2 billion at September 30, 2021, consisting of $754 million of current debt and $17.446 billion of long-term debt, versus $18.534 billion at year-end 2020.
- Abbott had $5.0 billion of committed lines of credit expiring in 2025. Long-term debt ratings were A+ from Standard & Poor’s and A2 from Moody’s.
Material changes versus the prior comparable period
- Diagnostics sales increased 48.2% in Q3 and 73.0% for the first nine months; nine-month sales reached $11.173 billion versus $6.460 billion in 2020. Rapid Diagnostics drove much of the increase because of COVID-19 testing demand.
- Q3 COVID-19 testing-related sales were approximately $1.9 billion versus $0.9 billion in Q3 2020. Nine-month COVID-19 testing-related sales were approximately $5.4 billion versus $1.5 billion in 2020.
- Excluding COVID-19 testing sales and foreign exchange, total sales increased 12.1% in Q3 and 14.9% for the first nine months.
- Nine-month Medical Devices sales increased 24.5% to $10.618 billion, led by Diabetes Care, Structural Heart, and Electrophysiology. FreeStyle Libre and Libre Sense sales increased 37.2% excluding foreign exchange to approximately $2.7 billion.
- Research and development expense increased 15.0% for the first nine months, while selling, general and administrative expense increased 16.1%, primarily reflecting higher spending to support growth and the nonrecurrence of $100 million of 2020 litigation-settlement income.
- Gross margin improved primarily from higher volumes, manufacturing utilization, the nonrecurrence of a 2020 intangible-asset impairment, and changes in COVID-19 diagnostic restructuring estimates.
- Abbott declared quarterly dividends of $0.45 per share in each of the first three quarters, a 25% increase from $0.36 per share in 2020. The company repurchased approximately 10.1 million shares for $1.187 billion during the first nine months.
Guidance, outlook, risks, contingencies, and unusual items
- The filing does not provide a clear quantitative full-year earnings or revenue guidance figure.
- COVID-19 testing demand remained a significant growth driver, but management stated that the duration and future financial impact of the pandemic are uncertain. Demand changed materially with vaccination rates, case levels, variants, and testing guidance.
- Abbott recorded $499 million of second-quarter restructuring charges related to its COVID-19 diagnostic-test manufacturing network. In Q3, it sold approximately $120 million of inventory previously considered to have no net realizable value and reduced estimated exit costs by $19 million. The remaining related accrual was $98 million at September 30.
- Abbott acquired Walk Vascular in September 2021. The acquisition’s purchase accounting, revenue, and net income impact were not material.
- Remaining performance obligations were approximately $3.9 billion in Diagnostics and $445 million in Medical Devices. Abbott expects to recognize approximately 60% over the next 24 months and 16% over the subsequent 12 months.
- Legal and environmental proceedings had an estimated possible loss range of approximately $25 million to $45 million, with a recorded accrual of approximately $35 million. Management does not expect the ultimate resolution to have a material adverse effect, although outcomes remain uncertain.
- Abbott estimated that approximately $80 million of gross unrecognized tax benefits could decrease within the next 12 months as tax matters are resolved.
- Key ongoing risks include healthcare regulation and reimbursement, competition, foreign-exchange movements, product approvals and performance, supply and manufacturing conditions, procedure volumes, litigation, tax matters, and the uncertain trajectory of COVID-19 testing demand.
Most important facts for investors to verify
- Whether COVID-19 diagnostic sales and margins normalize as pandemic testing demand changes.
- The sustainability of underlying, non-COVID sales growth, particularly in Medical Devices and base Diagnostics.
- Execution of the COVID-19 diagnostic manufacturing restructuring and any additional charges or reversals.
- Cash conversion, inventory levels, capital expenditures, share repurchases, and dividend growth relative to operating cash flow.
- Debt maturities, refinancing activity, and preservation of Abbott’s investment-grade credit ratings.
- Material developments in litigation, tax audits, regulatory approvals, reimbursement, and product liability matters.